Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03781414 · ClinicalTrials.gov registry record · Phase 2
Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Liver Transplant Recipients With Additional 12-month Follow-up and Long-term Extension
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 129
- Enrollment target
NCT03781414 is a Phase 2 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 129 participants.
The verdict
NCT03781414, a Phase 2 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 129 participants
- Enrollment target
Study Summary
This was a multicenter, open-label, active-controlled study to evaluate the efficacy, safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of two CFZ533 maintenance doses in de novo liver transplant recipients.
Interventions
- BIOLOGICAL CFZ533
- DRUG Tacrolimus - MMF - corticosteroids
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 129 participants |
| Start Date | 2019-10-07 |
| Est. Completion | 2023-04-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03781414
The ClinicalTrials.gov registry entry for NCT03781414 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 129 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which CFZ533 is the first listed.
NCT03781414 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03781414 about?
NCT03781414 is a clinical study titled "Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Liver Transplant Recipients With Additional 12-month Follow-up and Long-term Extension". This was a multicenter, open-label, active-controlled study to evaluate the efficacy, safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of two CFZ533 maintenance doses in de novo liver transplant recipients.
What is the current status of trial NCT03781414?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 129 participants. The study started on 2019-10-07. Estimated completion is 2023-04-20.
What interventions are being tested in trial NCT03781414?
The interventions under investigation include: CFZ533 (BIOLOGICAL), Tacrolimus - MMF - corticosteroids (DRUG).
Who is sponsoring clinical trial NCT03781414?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.